Disease Diagnosis TRIZ Cases

Targeted RNA biomarkers diagnose heatstroke, bypassing complex whole-genome analysis to improve accuracy and speed.

Measuring neutrophil extracellular trap levels in blood samples selects responsive patients, reducing resource waste on non-responders.

A CCL23 splice variant immunoassay differentiates sepsis from non-septic systemic inflammatory response syndrome.

An automated system profiles glycan distribution patterns on cancer cells using specific adsorbents to establish a quantitative grading index.

A rapid detection kit for myocardial infarction utilizing a chromatographic membrane with three distinct test lines.

Combining multiple immunoassay results improves diagnostic accuracy to distinguish renal dysfunction from pulmonary embolism.

Humanized VEGF transgenic mice resolve model relevance gaps by enabling accurate angiogenesis therapy screening.

A multiplexed assay measures multiple biomarkers simultaneously to diagnose liver disorders.

Detecting biosignatures comprising hepatocyte growth factor and Spondin-1 in blood samples identifies patient predisposition to severe disease episodes.

PCR-based HLA-A*32:01 detection prevents vancomycin-induced DRESS by enabling alternative antibiotic selection, eliminating life-threatening morbidity.

A biomarker assay detects UCH-L1 and GFAP proteins to identify traumatic brain injury.

MMP-23 expression predicts immunotherapy response; inhibitors block Kv1.3 channels to restore T-cell function and enhance melanoma treatment.

Targeting PCDH7 polypeptides enables immunosuppressive therapy without extensive antigen testing, reducing diagnostic time and cost.

Combines sorafenib with GW5074 to dissociate the c-Raf and DAPK protein complex, overcoming drug resistance and reducing side effects.

BH3 profiling predicts chemosensitivity by measuring mitochondrial outer membrane permeabilization induced by specific peptides.

Targeting Spt7 and Spt8 genes within the SAGA complex alters H3K18 acetylation, resolving the trade-off between cell growth and longevity.

A thermostable glucose biosensor uses a binding protein and ngmFRET reporter for precise detection.

Evaluating baseline serum soluble IFNAR2 concentrations via ELISA predicts interferon beta responsiveness, avoiding complex gene expression analysis.

A multiplexed cytokine assay kit uses discrete binding domains for simultaneous quantification.

Detecting antibodies against 5'-nucleotidase enables specific identification of inclusion body myositis through serological testing.

CXCL8 receptor inhibitors block inflammatory signaling to restore wildtype hematopoietic stem cell proliferation.

A single tube containing 22 to 24 antibodies enables comprehensive immunotyping of myeloid neoplasms.

Agents modulate CD19 glycosylation states to restore CAR T cell recognition of malignant B cells.

Immunoassay detects Flt1, MMP-10, PIGF, CA125, IL-6, and IL-8 levels in patient samples to identify cancerous conditions.

Elevated glycosylated fibronectin concentrations predict adverse pregnancy outcomes, addressing inadequate diagnostic precision in current screening tools.

Specific protein biomarkers in blood samples predict abdominal aortic aneurysm growth rates.

A handheld breath analyzer detects hydrogen levels in exhaled air using a selective sensor material to identify gastrointestinal disorders.

Extracting GFAP and UCH-L1 biomarkers from blood replaces complex imaging, reducing diagnostic time while maintaining accuracy.

Nanobar arrays facilitate optical Ras clustering detection, resolving low sensitivity in drug screening by mapping isoform mutations.

Quantitating autoantibodies on T lymphocytes via flow cytometry enables precise detection of systemic lupus erythematosus.

Immunohistochemical panels detect specific biomarker proteins to classify medulloblastoma molecular subgroups.

A biomarker analysis method classifies pediatric patients into risk categories using IL-8 and CCL3 levels measured after cardiopulmonary bypass.

Ketogenic fasting-mimicking diets reduce p16INK4a-positive cells via autophagy, addressing chronic inflammation and tissue deterioration.

Measuring SAA, CRP, and MxA concentrations differentiates infectious from inflammatory conditions, reducing unnecessary antimicrobial use.

Detect monomeric myeloperoxidase via antibody assays to diagnose endometriosis without invasive surgery.

Molecular marker selection identifies causal genes to replace time-consuming phenotypic evaluation in breeding programs.

A multiplexed targeted proteomics assay quantifies neurodegenerative disease biomarkers using mass spectrometry.

A rapid sepsis test detects abnormal CD49e, CD14, CD11c, CD49f, and CD29 expressions on leucocytes using flow cytometry.

Measuring prothrombin fragment F1+2 replaces complex manual processing to automate heparin-induced thrombocytopenia diagnosis and assess acute thrombotic risk.

Polystyrene surface adsorption quantifies apolipoprotein isoforms, eliminating complex genetic analysis and reducing clinical implementation barriers.

Lipocalin 2 serves as a biomarker to assess treatment efficacy, resolving the lack of effective monitoring tools for IL-17 inhibitor therapies.

A multi-biomarker diagnostic system measures urine and serum levels to detect kidney injury stages.

Measuring specific vasoactive hormone fragments in bodily fluids to stratify patients into responder categories, preventing adverse medication effects.

Segmented citrullinated 14-3-3eta peptides detect disease-specific autoantibodies in anti-CCP negative patients.